Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small …
Results A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1
tumors and 11 patients with T2 tumors) with a median follow-up of 4.0 years (7.2 years for
surviving patients). Four patients had an in-field/marginal (primary) tumor failure (range, 1.8-
4.8 years after SBRT); the estimated 5-year primary tumor failure rate was 7%. Nine
additional patients had recurrence within the involved lobe (range 0.1-5.9 years after SBRT);
the 5-year primary tumor and involved lobe (local) failure rate was 20%. Seven patients …
tumors and 11 patients with T2 tumors) with a median follow-up of 4.0 years (7.2 years for
surviving patients). Four patients had an in-field/marginal (primary) tumor failure (range, 1.8-
4.8 years after SBRT); the estimated 5-year primary tumor failure rate was 7%. Nine
additional patients had recurrence within the involved lobe (range 0.1-5.9 years after SBRT);
the 5-year primary tumor and involved lobe (local) failure rate was 20%. Seven patients …